Technology ID
TT-0122
Description
Our platform targets cancer and precancerous cells’ DNA replication-initiation proteins (DRIPs) with DRIP inhibitors, offering a transformative approach for treating various cancers and precancerous conditions. It also holds potential application value in viral warts and other abnormal proliferative diseases. The first-in-class EN002-gel is in Phase II clinical trial stage, with a 90% cure rate for skin precancerous lesions, highlighting our solution’s market promise. EK4-106 gel for cervical cancer and precancerous lesions is in preclinical stage, and more candidates are being studies for other cancers.
Content
Broad Application: Pioneering treatments for a wide array of cancers and precancerous lesions
Competitive Advantage: Exceptional potency and safety, offering significant improvements over current cancer therapies and filling the gap in the treatment for precancerous lesions
Commercial Progress: Successful Phase I clinical trial and ongoing Phase II, signaling rapid progress towards market entry
Inventors
Applicable Industries
Potential Application
Technology Focus
TRL
Images
